These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21623646)

  • 1. Attitudes of health care professionals toward pharmacogenetic testing.
    Zgheib NK; Arawi T; Mahfouz RA; Sabra R
    Mol Diagn Ther; 2011 Apr; 15(2):115-22. PubMed ID: 21623646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS.
    Fargher EA; Eddy C; Newman W; Qasim F; Tricker K; Elliott RA; Payne K
    Pharmacogenomics; 2007 Nov; 8(11):1511-9. PubMed ID: 18034616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of healthcare professionals' knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt.
    Nagy M; Lynch M; Kamal S; Mohamed S; Hadad A; Abouelnaga S; Aquilante CL
    Per Med; 2020 Jul; 17(4):251-260. PubMed ID: 32589096
    [No Abstract]   [Full Text] [Related]  

  • 4. Consent and privacy in pharmacogenetic testing.
    Robertson JA
    Nat Genet; 2001 Jul; 28(3):207-9. PubMed ID: 11431685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive perception of pharmacogenetic testing for psychotropic medications.
    Lanktree MB; Zai G; Vanderbeek LE; Giuffra DE; Smithson DS; Kipp LB; Dalseg TR; Speechley M; Kennedy JL
    Hum Psychopharmacol; 2014 May; 29(3):287-91. PubMed ID: 24604560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics in future medical care -- implications for patients and physicians].
    Rogausch A; Brockmöller J; Himmel W
    Gesundheitswesen; 2005 Apr; 67(4):257-63. PubMed ID: 15856385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' and physicians' perspectives on pharmacogenetic testing.
    Rogausch A; Prause D; Schallenberg A; Brockmöller J; Himmel W
    Pharmacogenomics; 2006 Jan; 7(1):49-59. PubMed ID: 16354124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Context, ethics and pharmacogenetics.
    Hedgecoe AM
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):566-82. PubMed ID: 16980195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic testing: not as simple as it seems.
    Haga SB; Burke W
    Genet Med; 2008 Jun; 10(6):391-5. PubMed ID: 18496219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic testing, informed consent and the problem of secondary information.
    Netzer C; Biller-Andorno N
    Bioethics; 2004 Aug; 18(4):344-60. PubMed ID: 15449406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
    Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
    Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics--legal, ethical and regulatory considerations.
    March R; Cheeseman K; Doherty M
    Pharmacogenomics; 2001 Nov; 2(4):317-27. PubMed ID: 11722282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge and attitudes toward electroconvulsive therapy among health care professionals and students.
    Byrne P; Cassidy B; Higgins P
    J ECT; 2006 Jun; 22(2):133-8. PubMed ID: 16801830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
    Caudle KE; Dunnenberger HM; Freimuth RR; Peterson JF; Burlison JD; Whirl-Carrillo M; Scott SA; Rehm HL; Williams MS; Klein TE; Relling MV; Hoffman JM
    Genet Med; 2017 Feb; 19(2):215-223. PubMed ID: 27441996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.
    Morley KI; Hall WD
    J Mol Med (Berl); 2004 Jan; 82(1):21-30. PubMed ID: 14598045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ancillary risk information and pharmacogenetic tests: social and policy implications.
    Henrikson NB; Burke W; Veenstra DL
    Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry.
    Hoop JG; Lapid MI; Paulson RM; Roberts LW
    J Clin Psychiatry; 2010 Jun; 71(6):745-53. PubMed ID: 20361898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes towards informed consent, confidentiality, and substitute treatment decisions in southern African medical students: a case study from Zimbabwe.
    Hipshman L
    Soc Sci Med; 1999 Aug; 49(3):313-28. PubMed ID: 10414817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pharmacists from the province of Quebec ready to integrate pharmacogenetics into their practice.
    Petit C; Croisetière A; Chen F; Laverdière I
    Pharmacogenomics; 2020 Mar; 21(4):247-256. PubMed ID: 32180495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.